(VIANEWS) – Progyny (PGNY), Copart (CPRT), Incyte Corporation (INCY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Progyny (PGNY)
15.7% sales growth and 12.3% return on equity
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Progyny has a trailing twelve months EPS of $0.61.
PE Ratio
Progyny has a trailing twelve months price to earnings ratio of 48.61. Meaning, the purchaser of the share is investing $48.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.3%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 13.3% and 25%, respectively.
Yearly Top and Bottom Value
Progyny’s stock is valued at $29.65 at 20:22 EST, way below its 52-week high of $44.95 and way higher than its 52-week low of $23.90.
Moving Average
Progyny’s worth is higher than its 50-day moving average of $28.00 and way below its 200-day moving average of $33.50.
Volume
Today’s last reported volume for Progyny is 267325 which is 77.46% below its average volume of 1186050.
2. Copart (CPRT)
13.5% sales growth and 21.71% return on equity
Copart, Inc. provides online auctions and vehicle remarketing services in the United States, Canada, the United Kingdom, Brazil, the Republic of Ireland, Germany, Finland, the United Arab Emirates, Oman, Bahrain, and Spain. It offers a range of services for processing and selling vehicles over the internet through its virtual bidding third generation internet auction-style sales technology to vehicle sellers, insurance companies, banks and finance companies, charities, fleet operators, dealers, vehicle rental companies, and individuals. The company's services include online seller access, salvage estimation, estimating, end-of-life vehicle processing, transportation, vehicle inspection stations, on-demand reporting, title processing and procurement, loan payoff, flexible vehicle processing programs, buy it now, member network, sales process, and dealer services. Its services also comprise services to sell vehicles through CashForCars.com, CashForCars.ca, CashForCars.de, CashForCars.co.uk, and Cash-for-cars.ie; Copart Recycling service, which allows the public to purchase parts from salvaged and end-of-life vehicles; copart 360, an online technology for posting vehicle images that captures clear 360-degree views of interiors and exteriors of cars, trucks, and vans; membership tiers for those registering to buy vehicles through Copart.com; and virtual queue to secure a place in line while visiting one of its locations. In addition, it provides non-salvage powersport vehicle remarketing services through live and online auction platforms. The company sells its products principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, and exporters, as well as to the public. Copart, Inc. was incorporated in 1982 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Copart has a trailing twelve months EPS of $1.4.
PE Ratio
Copart has a trailing twelve months price to earnings ratio of 39.56. Meaning, the purchaser of the share is investing $39.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.71%.
Yearly Top and Bottom Value
Copart’s stock is valued at $55.38 at 20:22 EST, under its 52-week high of $58.58 and way higher than its 52-week low of $42.41.
Moving Average
Copart’s value is above its 50-day moving average of $54.01 and above its 200-day moving average of $51.32.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.3%, now sitting on 4.17B for the twelve trailing months.
3. Incyte Corporation (INCY)
9.5% sales growth and 15.13% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 20.32. Meaning, the purchaser of the share is investing $20.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.13%.
4. Scorpio Tankers (STNG)
8% sales growth and 21.39% return on equity
Scorpio Tankers Inc., together with its subsidiaries, engages in the seaborne transportation of crude oi and refined petroleum products in the shipping markets worldwide. As of March 21, 2024, its fleet consisted of 110 owned and leases financed tanker, including 39 LR2, 57 MR, and 14 Handymax with a weighted average age of approximately 8.1 years. Scorpio Tankers Inc. was incorporated in 2009 and is headquartered in Monaco.
Earnings Per Share
As for profitability, Scorpio Tankers has a trailing twelve months EPS of $10.87.
PE Ratio
Scorpio Tankers has a trailing twelve months price to earnings ratio of 7.04. Meaning, the purchaser of the share is investing $7.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.39%.
Volume
Today’s last reported volume for Scorpio Tankers is 740379 which is 2.51% below its average volume of 759500.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.8%, now sitting on 1.35B for the twelve trailing months.
5. Laureate Education (LAUR)
5.6% sales growth and 15.16% return on equity
Laureate Education, Inc., together with its subsidiaries, offers higher education programs and services to students through a network of universities and higher education institutions. The company provides a range of undergraduate and graduate degree programs in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs. It also offers specialized courses for technical and vocational training; and senior high school. Its services are provides in Mexico, Peru, and the United States. The company was formerly known as Sylvan Learning Systems, Inc. and changed its name to Laureate Education, Inc. in May 2004. Laureate Education, Inc. was founded in 1989 and is headquartered in Miami, Florida.
Earnings Per Share
As for profitability, Laureate Education has a trailing twelve months EPS of $0.84.
PE Ratio
Laureate Education has a trailing twelve months price to earnings ratio of 18.75. Meaning, the purchaser of the share is investing $18.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.16%.
Previous days news about Laureate Education(LAUR)
- Laureate education (laur) upgraded to strong buy: what does it mean for the stock?. According to Zacks on Thursday, 25 July, "The upgrade of Laureate Education to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.", "Investors might want to bet on Laureate Education (LAUR Quick QuoteLAUR – Free Report) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). "
